Rani Therapeutics announces preclinical data on oral triagonist and updates on pipeline milestones

Rani Therapeutics Holdings, Inc.

Preclinical study of incretin triagonist (GLP-1, GIP, glucagon) showed similar weight loss and lipid reduction via endoscope vs SC; no serious adverse events.
RT-102 (teriparatide for osteoporosis) Phase 2 trial expected to start in 2024.
Topline results from RT-111 Phase 1 (ustekinumab biosimilar) expected Q1 2024.
RaniPill HC development expected ready for Phase 1 trials in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.